The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
New early-phase knowledge offered on the 2025 American Society of Hematology Annual Assembly recommend that INCA033989, a first-in-class antibody concentrating on mutant...
Gedatolisib plus Faslodex (fulvestrant) with or with out Ibrance (palbociclib) continued to point out efficacy in comparison with Faslodex alone when used...
